We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
For the fourth quarter ended December 31, 2008, Sangamo reported a consolidated net loss of $2.6 million, or $0.06 per share, against a net loss of $6.7 million,
“We are very pleased to add Eric’s scientific expertise and leadership to our already strong senior management team,” said Carl Hull, Gen-Probe’s president and chief operating officer. “We
The new clinical development offices and expanded workforce will help Covance expedite the execution of clinical studies and build strategic relationships with investigators and sites in countries well
In his role at Quest, Leon held several positions over time, including director of molecular diagnostics, senior director of biotechnology department, and vice president of applied genomics. “We
Total revenue for the fourth quarter of 2008 increased to $31.2 million, compared with $19.3 million in the fourth quarter of 2007. Product revenue from the Oncotype DX(R)
QuantRx expects that the product will be launched by Church & Dwight under its First Response brand and will be available at the retail level in the second
Excluding restructuring charges in both fiscal 2008 and 2009, third quarter fiscal 2009 adjusted operating income was $25 million, up 20%, and adjusted earnings per share were $0.63,
Prior to the Dow appointment, she served as director of Research and Development for Biocor Animal Health (Biocor) where she was responsible for all aspects of design and
The company has reduced its headcount by 17 since June 2008, from 42 to 25, including the closure of its therapeutics business in Boston. This is the end
Sales in local currencies increased by 12% in 2008 and by 9% in Danish kroner. Sales of modern insulins increased by 28% (24% in Danish kroner). Sales of